Headlines

Bristol-Myers-Squibb (BMY) says the US FDA has accepted a New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Newsquawk Staff ·

Bristol-Myers-Squibb (BMY) says the US FDA has accepted a New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Related headlines